Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial
出版年份 2022 全文链接
标题
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial
作者
关键词
-
出版物
Future Oncology
Volume -, Issue -, Pages -
出版商
Future Medicine Ltd
发表日期
2022-05-24
DOI
10.2217/fon-2021-1629
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).
- (2021) Alison Jane Birtle et al. JOURNAL OF CLINICAL ONCOLOGY
- An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
- (2021) Thomas Powles et al. NATURE MEDICINE
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
- (2021) Dean F. Bajorin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
- (2021) Yung Lyou et al. Clinical Genitourinary Cancer
- Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
- (2021) Milind Javle et al. Lancet Gastroenterology & Hepatology
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2021) T. Powles et al. ANNALS OF ONCOLOGY
- Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
- (2020) Alison Birtle et al. LANCET
- Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results
- (2020) Sumanta K. Pal et al. CANCER
- Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
- (2020) Angela Lamarca et al. JOURNAL OF HEPATOLOGY
- Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy
- (2020) Jeffrey J. Leow et al. EUROPEAN UROLOGY
- Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma
- (2020) Yung Lyou et al. EUROPEAN UROLOGY
- Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor
- (2020) M. Teresa Magone et al. OPHTHALMOLOGY
- Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.
- (2019) Nazli Dizman et al. JOURNAL OF CLINICAL ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
- (2018) A. Gordon Robertson et al. CELL
- Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
- (2018) François Audenet et al. CLINICAL CANCER RESEARCH
- Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
- (2017) Eugene J. Pietzak et al. EUROPEAN UROLOGY
- Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma
- (2017) Tyler J. Moss et al. EUROPEAN UROLOGY
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
- (2017) Sam S. Chang et al. JOURNAL OF UROLOGY
- New option for cisplatin-ineligible urothelial cancer
- (2017) Robert Dreicer LANCET ONCOLOGY
- Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma
- (2016) Aditya Bagrodia et al. JOURNAL OF UROLOGY
- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations
- (2015) Jeffrey S. Ross et al. CANCER
- Genomic Characterization of Upper Tract Urothelial Carcinoma
- (2015) John P. Sfakianos et al. EUROPEAN UROLOGY
- European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update
- (2015) Morgan Rouprêt et al. EUROPEAN UROLOGY
- Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
- (2014) J. Bellmunt et al. ANNALS OF ONCOLOGY
- FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non-Small Cell Lung Cancer
- (2014) R. Wang et al. CLINICAL CANCER RESEARCH
- Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
- (2014) Mitesh J. Borad et al. PLoS Genetics
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease
- (2011) N. Itoh et al. JOURNAL OF BIOCHEMISTRY
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
- (2011) Matthew D Galsky et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now